Skip to main content

Table 1 Characteristics of eligible studies in this meta-analysis

From: PCAT6 may be a new prognostic biomarker in various cancers: a meta-analysis and bioinformatics analysis

ID Year Country Sample size (high/low) Cancer type Method Outcomes HR availability Follow-up months (mouth) NOS Score
Zhu 2020 [35] 2020 China 60 (30/30) Osteosarcoma qRT-PCR OS, PFS, CP K-M curve 60 5
Lv 2019 [27] 2019 China 114 (58/56) Cervical cancer qRT-PCR OS, PFS, CP K-M curve 60 6
Wan 2016 [18] 2016 China 58 (27/31) Lung cancer qRT-PCR OS, CP K-M curve 60 6
Wang 2020 [28] 2020 China 67 (37/30) Pancreatic ductal adenocarcinoma qRT-PCR OS, CP K-M curve 60 6
Wu 2019 [26] 2019 China 73 (37/36) Colorectal cancer qRT-PCR OS, CP K-M curve 60 6
Wu 2020 [23] 2020 China 106 (70/36) Osteosarcoma qRT-PCR OS, PFS, CP K-M curve 60 6
Zhang 2020 [34] 2020 China 106 (53/53) Bladder cancer qRT-PCR OS, PFS, CP K-M curve 150 7
Xu 2018 [33] 2018 China 72 (36/36) Gastric cancer qRT-PCR OS, CP K-M curve 100 6
Shi 2018 [25] 2018 China 60 (31/29) Lung cancer qRT-PCR CP K-M curve 6
Kong 2019 [24] 2019 China 42 (18/24) Ovarian cancer qRT-PCR CP K-M curve 6
  1. OS overall survival, PFS progression-free survival, CP clinicopathological parameters, NOS Newcastle–Ottawa Scale, K-M curve Kaplan–Meier curve, qRT-PCR quantitative real time polymerase chain reaction, -, not available or invalid